日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding.

HER2-HER3异二聚体和去乙酰化FOXA1的协调活动通过调节FOXA1染色质结合来逃避激素反应。

Wang Shixiong, Santacana-Font Gemma, Kedra Darek, Gilfillan Siv, Tena-Chaves David, Bergholtz Helga, Engebraaten Olav, Lingjaerde Ole Christian, Gutiérrez-Fernández Javier, Norum Jens Henrik, Sørlie Therese, López-Aviles Sandra, Hurtado Antoni

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy

在HER2阴性乳腺癌患者中,新辅助化疗后治疗中期肿瘤RNA破坏程度较高与无病生存期延长相关。

Parissenti, Amadeo M; Pritzker, Laura B; Dahle, Maria Aanesland; Gythfeldt, Hedda von der Lippe; Masilamani, Twinkle; Theriault, Gabriel; St-Onge, Renée; D'costa, Lavina; Lingjaerde, Ole Christian; Haugen, Mads Haugland; Engebraaten, Olav

Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.

化疗耐药肿瘤细胞分泌组增强了三阴性乳腺癌的免疫抑制作用

Skourti Eleni, Seip Kotryna, Mensali Nadia, Jabeen Shakila, Juell Siri, Øynebråten Inger, Pettersen Solveig, Engebraaten Olav, Corthay Alexandre, Inderberg Else Marit, Dolznig Helmut, Mælandsmo Gunhild Mari, Egeland Eivind Valen, Prasmickaite Lina

The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases.

HER2靶向抗体药物偶联物的作用机制依赖于Rab GTP酶

Medhus Astrid, Schink Kay Oliver, Longva Ane Sager, Engebraaten Olav, Berg Kristian, Weyergang Anette

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

曲妥珠单抗德鲁替康联合生物学驱动的新辅助治疗方案选择在HER2阳性乳腺癌中的随机对照试验:ARIADNE研究方案

Matikas, Alexios; Naume, Bjørn; Wildiers, Hans; Sonke, Gabe; Dieci, Maria Vittoria; Karakatsanis, Andreas; Andersson, Anne; Barnekow, Elin; Kessler, Luisa Edman; Einbeigi, Zakaria; Killander, Fredrika; Linderholm, Barbro; Schiza, Aglaia; Valachis, Antonis; Nearchou, Andreas; Engebraaten, Olav; Porojnicu, Alina; Soland, Mari Hiorth; Mannsåker, Bård; Raj, Sunil X; Blix, Egil Støre; Nordstrand, Cecilie Soma; Lambertini, Matteo; Vernieri, Claudio; Punie, Kevin; Sotiriou, Christos; Bergh, Jonas; Villacampa, Guillermo; Zouzos, Athanasios; Hellström, Mats; Hartman, Johan; Foukakis, Theodoros

Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response

ER阳性乳腺癌肿瘤免疫微环境的空间组织:治疗期间的重塑及其与临床反应的关系

Dahle, Maria Aanesland; Førde, Jan-Lukas; Egeland, Eivind Valen; Creason, Allison L; Watson, Cameron; Garred, Øystein; Prasmickaite, Lina; Mælandsmo, Gunhild M; Mills, Gordon B; Engebraaten, Olav; Haugen, Mads Haugland

Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)

Prosigna 检测对淋巴结阴性早期乳腺癌辅助治疗决策的影响——一项前瞻性全国多中心研究 (EMIT-1)

Ohnstad, H O; Blix, E S; Akslen, L A; Gilje, B; Raj, S X; Skjerven, H; Borgen, E; Janssen, E A M; Mortensen, E; Brekke, M B; Falk, R S; Schlichting, E; Boge, B; Songe-Møller, S; Olsson, P; Heie, A; Mannsåker, B; Vestlid, M A; Kursetgjerde, T; Gravdehaug, B; Suhrke, P; Sanchez, E; Bublevic, J; Røe, O D; Geitvik, G A; Halset, E H; Rypdal, M C; Langerød, A; Lømo, J; Garred, Ø; Porojnicu, A; Engebraaten, O; Geisler, J; Lyngra, M; Hansen, M H; Søiland, H; Nakken, T; Asphaug, L; Kristensen, V; Sørlie, T; Nygård, J F; Kiserud, C E; Reinertsen, K V; Russnes, H G; Naume, B

The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy

SRC家族是三阴性乳腺癌(对化疗产生耐药性)的治疗靶点。

Egeland, Eivind Valen; Seip, Kotryna; Skourti, Eleni; Øy, Geir Frode; Pettersen, Solveig J; Pandya, Abhilash D; Dahle, Maria A; Haugen, Mads H; Kristian, Alexander; Nakken, Sigve; Engebraaten, Olav; Mælandsmo, Gunhild M; Prasmickaite, Lina

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer

整合组学方法揭示了表观遗传事件如何解释和预测乳腺癌患者对新辅助化疗和贝伐单抗的反应。

Fleischer, Thomas; Haugen, Mads Haugland; Ankill, Jørgen; Silwal-Pandit, Laxmi; Børresen-Dale, Anne-Lise; Hedenfalk, Ingrid; Hatschek, Thomas; Tost, Jörg; Engebraaten, Olav; Kristensen, Vessela N

Liver X receptors induce antiproliferative effects in basal-like breast cancer

肝脏 X 受体在基底样乳腺癌中诱导抗增殖作用

Mads Haugland Haugen, Hedda von der Lippe Gythfeldt, Eivind Valen Egeland, Lisa Svartdal Normann, Abhilash D Pandya, Lise-Lotte Vedin, Siri Juell, Ellen Tenstad, Geir Frode Øy, Alexandr Kristian, Elisabetta Marangoni, Therese Sørlie, Knut Steffensen, Gunhild Mari Maelandsmo, Olav Engebraaten